Industry Insights

  1. Solving Vector Yield Challenges Starts Long Before Manufacturing 7/22/2026

    Cell & Gene Live panelists take a deep dive into why solving vector yield challenges begins with early biological and manufacturing decisions rather than process optimization alone.

  2. The Missing Layer: Why CAR-T Needs AI As Its Connective Tissue 7/21/2026

    AI can close CAR-T’s access gap by replacing fragmented community delivery handoffs with automated orchestration across referral, reimbursement, logistics, and monitoring.

  3. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.

  4. Unlocking Gentler, Cost-Efficient TIL Therapy For Cold Tumors 7/20/2026

    CuraCell Head of Clinical Operations Torbjörn Ström discusses, in the context of CC-38 and CytoPLY-derived tumor-infiltrating lymphocytes (TILs), the utility of named-patient experience, dosing and preconditioning, and T-cell therapy capabilities in cold solid tumors.

  5. Full FDA Approval For TECELRA Marks More Than A Regulatory Win For Solid Tumors 7/17/2026

    US WorldMeds' expanded FDA approval for TECELRA represents another important step forward for engineered cell therapies in solid tumors.

  6. Addressing The Particulate Challenge In Cell Therapy Products 7/15/2026

    Cell therapy products challenge traditional particulate controls. One expert explains detection, mitigation, and contamination prevention.

  7. Let's Stop Treating Allogeneic Cell Therapy As One Thing 7/14/2026

    Industry is beginning to accept that allogeneic cell therapy spans categories, and success depends on aligning biology, regulation, and economics unique to each product.

  8. Allogeneic Cell Therapy Is Still Learning What Biology Will Allow 7/14/2026

    Allogeneic cell therapy is advancing through smarter donor selection and manufacturing control, showing how biology, process design, and product consistency drive success.

  9. Reassessing Nanoparticle Immunotoxicity: From Well-Established To Novel Approaches 7/14/2026

    This article highlights government-funded resources available to de-risk nanomedicines, reviews principles of immunotoxicity testing, and discusses emerging methodologies.

  10. Building CGT Manufacturing Capacity For The Next Commercial Era 7/13/2026

    Recent investments — mostly by CDMOs — are expanding manufacturing capacity to support the growing cell and gene therapy pipeline. We also discuss associated trends and impacts.